Karakteristik dan Keluaran Pasien COVID-19 dengan DM di RS Umum Pusat Dr. Kariadi (Tinjauan pasien periode Maret-Juli 2020)
DOI:
https://doi.org/10.36408/mhjcm.v7i1A.473Keywords:
COVID-19, DM, RS KariadiAbstract
Pendahuluan
Jawa Tengah merupakan propinsi dengan kasus COVID-19 terbanyak ke-4 di Indonesia (lebih dari 8.000 kasus). RS Umum Pusat Dr. Kariadi (RSDK) sebagai RS rujukan memiliki 436 kasus terkonfirmasi COVID-19 per 10 Juli 2020. Diabetes mellitus (DM) diketahui menurunkan sistem imun dan memperburuk reaksi inflamasi. Karakteristik dan keluaran pasien COVID-19 dengan DM di RSDK belum pernah dilaporkan sebelumnya.
Metode
Data dari rekam medis RSDK. Diagnosis DM: riwayat DM dan/atau GDS >200 mg/dL atau HbA1c >7%. Diagnosis COVID-19: PCR usapan nasofaring-orofaring positif. Karakteristik dasar: usia, jenis kelamin, keluhan, riwayat kontak, riwayat perjalanan, jenis dan tempat perawatan, lama perawatan, komorbid, serta terapi DM. Pemeriksaan penunjang: GDS, HbA1c, kreatinin, saturasi O2, C-reactive protein (CRP), proklasitonin, D-dimer, dan fibrinogen dikelompokkan berdasarkan keluaran (hidup vs. mati); dilakukan uji beda. Analisis dengan SPSS v.24 (IBM, New York, USA).
Hasil
Pasien COVID-19 dengan DM periode Maret-10 Juli 2020 sebanyak 42 dari total 436 kasus (9,63%). Pria lebih banyak (59,5%). Kasus terbanyak usia >50 tahun (64,3%). Batuk, demam, dan sesak nafas adalah keluhan tersering. Mayoritas pasien menyangkal riwayat kontak ataupun bepergian (>75%). Hampir separuh perlu perawatan intensif sejak awal (40,5%). Komorbid terbanyak hipertensi. Separuh kasus mendapat insulin. Persentase kematian 42,9% (18 dari 42). Rerata kendali glikemik (HbA1c 9,7%) dan saturasi O2 (Sat O2 90%) buruk. Rerata penanda gangguan koagulasi (D-dimer, fibrinogen) dan inflamasi akut (CRP, prokalsitonin) meningkat, berturut-turut 3937,4 ng/mL; 496,1 mg/dL; 16,6 mg/L; 12 ng/mL. Tidak ada beda bermakna antara kelompok hidup dan mati.
Kesimpulan
Mortalitas dan morbiditas COVID-19 sangat tinggi pada DM. Hampir seluruh pasien mengalami gangguan koagulasi dan inflamasi akut.
Kata kunci: COVID-19, DM, RS Kariadi
Introduction
Central Java province has the 4th largest cases of COVID-19 in Indonesia with more than 8.000 cases. Dr. Kariadi General Hospital (RSDK) is one of the referral hospital with 436 confirmed cases of COVID-19 until July 10th 2020. Diabetes mellitus (DM) known to decreases the immune system and worsens the inflammatory reaction. The characteristics and outcomes of patients with COVID-19 and DM in the RSDK have not been reported yet.
Method
Data were taken from the RSDK medical record. Diagnosis of DM: history of diabetes and/or RBG >200 mg/dL or HbA1c >7%. Diagnosis of COVID-19 infection: positive PCR from nasopharyngeal-oropharyngeal smear. Baseline characteristics: age, sex, chief complaints, contact and travel history, type and place of care, duration of treatment, comorbidity, and diabetes treatment options. Laboratory result: RBG, HbA1c, creatinine, O2 saturation, C-reactive protein (CRP), proclasitonin, D-dimers, and fibrinogen were grouped according to patient output (life vs. death) and different tests was performed. Data analysis was performed with SPSS v.24 (IBM, New York, USA).
Result
The number of patients with COVID-19 and DM was 42 out of 436 cases (9.63%). Men was more prevalent (59.5%). Most cases were >50 years of age (64.3%). Cough, fever, and shortness of breath were the most prevalent chief complaints. The majority of patients denied contact or travel history (>75%). Nearly half of the cases needed intensive care (40.5%) at arrival. Hypertension was the no.1 comorbid. Half cases received insulin therapy. Percentage of death was 42.9% (18 out of 42). Average of glycemic control (HbA1c 9.7%) and O2 saturation (Sat O2 90%) were poor. Coagulation (D-dimer, fibrinogen) and acute inflammatory (CRP, procalsitonin) markers were increased, respectively 3937.4 ng/mL; 496.1 mg/dL; 16.6 mg/L; 12 ng/mL. There was no significant difference between the life and death groups.
Conclusion
Mortality and morbidity of patients with COVID-19 and DM was very high. Almost all patients suffered from disseminated intravascular coagulation (DIC) and severe acute inflammation.
Key words: COVID-19, DM, Kariadi Hospital
Downloads
References
2. WHO Coronavirus Disease (COVID-19) situation report by 12 July 2020 available at https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200712-covid-19-sitrep-174.pdf?sfvrsn=5d1c1b2c_2
3. Beranda Gugus Tugas Penanganan COVID-19 available at https://covid19.go.id
4. SIM RS Umum Pusat Dr. Kariadi Semarang
5. Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, et al. Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 2016;22(1):49–55.
6. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23(6):623–8.
7. Infodatin 2018 available at file:///C:/Users/hp/AppData/Local/Temp/infodatin-Diabetes-2018.pdf
8. Muniyappa R, Gubbi S. COVID-19 Pandemic, Corona Viruses, and Diabetes Mellitus. Am J Physiol Endocrinol Metab 2020;736–41.
9. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest [Internet]. 2020;43(6):867–9. Available from: https://doi.org/10.1007/s40618-020-01236-2
10. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet [Internet]. 2020;395(10231):1225–8. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30627-9
11. Organization WH. Use of glycated hemoglobin (HbA1c) in the diagnosis of diabetes mellitus abbreviated report of a WHO consultation. 2011
12. Kriteria usia oleh Depkes RI available at www.scribd.com/doc/151484440/Kategori-Umur-Menurut-Depkes-RI
13. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 2020;8(April):1–6.
14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet [Internet]. 2020;395(10223):507–13. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30211-7
15. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med [Internet]. 2020;8(4):e20. Available from: http://dx.doi.org/10.1016/S2213-2600(20)30117-X
16. Walter LA MA. Sex-and Gender-specific Observations and Implications for COVID-19. West J Emerg Med Integr Emerg Care with Popul Heal 2020
17. Cornelia MW and Jorg JG. Aging of the Immune System. Mechanisms and Therapeutic Targets. Ann Am Thorac Soc 2016; 13(Suppl 5): S422–8
18. Hafeez A, Ahmad S, Siddqui SA, Ahmad M, Mishra S. A review of COVID-19 (Coronavirus Disease-2019) diagnosis, treatments and prevention. EJMO 2020;4(2):116–25
19. Tanggap COVID-19 Propinsi Jawa Tengah available at https://corona.jatengprov.go.id/berita
20. Hill MA, Mantzoros C, Sowers JR. Commentary: COVID -19 in patients with diabetes. J Metabol 2020 available at https://doi.org/10.1016/j.metabol.2020.154217
21. Sandooja R, Vura NVRK, Morocco M. Heightened ACE Activity and Unfavorable Consequences inCOVID-19 Diabetic Subjects. Int J Endocrinol 2020 available at https://doi.org/10.1155/2020/7847526
22. Sardu C, D’Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, et al. Outcomes in Patients With Hyperglycemia Affected by Covid-19: Can We Do More on Glycemic Control? available at https://doi.org/10.2337/dc20-0723
23. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case. control study. J Intensive Care 2020;8:49
24. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 2020;43(7):1399–407.
25. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. available at https://doi.org/10.1016/j.ijantimicag.2020.106051
26. Valizadeh R, Baradaran A, Mirzazadeh A, Bhaskar LVKS. Coronavirus-nephropathy; renal involvement in COVID-19. J Renal Inj Prev 2020; 9(2): e18.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2020 Medica Hospitalia : Journal of Clinical Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
